Funder: Alzheimer's Association
Due Dates: March 26, 2026 (LOI) | April 30, 2026 (Full application)
Funding Amounts: Up to $2,000,000 (Phase 2-3, 2–3 years); up to $1,000,000 (Phase 1); rare cases up to $3,000,000 considered.
Summary: Supports clinical trials testing innovative, biomarker-driven combination therapies for Alzheimer’s disease and related dementias.
Key Information: LOI required; only one application per PI per cycle; indirect costs capped at 10% for non-profits, none for for-profits.